ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

NCT01304693 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Exudative Age-Related Macular Degeneration

Interventions

BIOLOGICAL: ESBA1008 solution
BIOLOGICAL: Ranibizumab 0.5 mg

Sponsor

Alcon Research